Mechanisms of dyslipoproteinemias in systemic lupus erythematosus

被引：64

作者：

Borba, Eduardo F. ^{[1
]}

Carvalho, Jozelio F. ^{[1
]}

Bonfa, Eloisa ^{[1
]}

机构：

[1] Sao Paulo Univ Hosp, Div Rheumatol, Sch Med, Sao Paulo, Brazil

来源：

CLINICAL & DEVELOPMENTAL IMMUNOLOGY | 2006年 / 13卷 / 2-4期

关键词：

systemic lupus erythematosus; lipoprotein; dyslipoproteinemia; hyperlipidemia; atherosclerosis; inflammation;

D O I：

10.1080/17402520600876945

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Autoimmunity and inflammation are associated with marked changes in lipid and lipoprotein metabolism in SLE. .Autoantibodies and cytokines are able to modulate lipoprotein lipase (LPL) activity, a key enzyme in lipid metabolism, with a consequent "lupus pattern" of dyslipoproteinemia characterized by elevated levels of very low-density lipoprotein cholesterol (VLDL) and triglycerides (TG) and lower high-density lipoprotein cholesterol (HDL) levels. This pattern favors an enhanced LDL oxidation with a subsequent deleterious foam cell formation. Autoantibodies and immunocomplexes may aggravate this oxidative injury by inducing accumulation and deposition of oxLDL in endothelial cells. Drugs and associated diseases usually magnify the close interaction of these factors and further promote the proatherogenic environment of this disease.

引用

页码：203 / 208

页数：6

共 102 条

[51] Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes [J].

Hyka, N ;

Dayer, JM ;

Modoux, C ;

Kohno, T ;

Edwards, CK ;

Roux-Lombard, P ;

Burger, D .

BLOOD, 2001, 97 (08) :2381-2389

[52] DYSLIPOPROTEINEMIA IN PEDIATRIC SYSTEMIC LUPUS-ERYTHEMATOSUS [J].

ILOWITE, NT ;

SAMUEL, P ;

GINZLER, E ;

JACOBSON, MS .

ARTHRITIS AND RHEUMATISM, 1988, 31 (07) :859-863

[53] Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice [J].

Inoue, S ;

Egashira, K ;

Ni, WH ;

Kitamoto, S ;

Usui, M ;

Otani, K ;

Ishibashi, M ;

Hiasa, K ;

Nishida, K ;

Takeshita, A .

CIRCULATION, 2002, 106 (21) :2700-2706

[54] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AS A PREDICTOR OF CARDIOVASCULAR-DISEASE MORTALITY IN MEN AND WOMEN - THE FOLLOW-UP-STUDY OF THE LIPID RESEARCH CLINICS PREVALENCE STUDY [J].

JACOBS, DR ;

MEBANE, IL ;

BANGDIWALA, SI ;

CRIQUI, MH ;

TYROLER, HA .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 1990, 131 (01) :32-47

[55] C-reactive protein: Risk marker or mediator in atherothrombosis? [J].

Jialal, I ;

Devaraj, S ;

Venugopal, SK .

HYPERTENSION, 2004, 44 (01) :6-11

[56] MENOPAUSE AND RISK OF CARDIOVASCULAR-DISEASE - FRAMINGHAM STUDY [J].

KANNEL, WB ;

HJORTLAND, MC ;

MCNAMARA, PM ;

GORDON, T .

ANNALS OF INTERNAL MEDICINE, 1976, 85 (04) :447-452

[57]

Kavanaugh A, 1997, J Clin Rheumatol, V3, P3, DOI 10.1097/00124743-199702000-00002

[58] Circulating oxidized LDL forms complexes with β2-glycoprotein I:: implication as an atherogenic autoantigen [J].

Kobayashi, K ;

Kishi, M ;

Atsumi, T ;

Bertolaccini, ML ;

Makino, H ;

Sakairi, N ;

Yamamoto, I ;

Yasuda, T ;

Khamashta, MA ;

Hughes, GRV ;

Koike, T ;

Voelker, DR ;

Matsuura, E .

JOURNAL OF LIPID RESEARCH, 2003, 44 (04) :716-726

[59]

Kobayashi K, 2001, J LIPID RES, V42, P697

[60] LOW-LEVELS OF TOTAL CHOLESTEROL, HIGH-DENSITY-LIPOPROTEIN, AND APOLIPOPROTEIN A1 IN ASSOCIATION WITH ANTICARDIOLIPIN ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].

LAHITA, RG ;

RIVKIN, E ;

CAVANAGH, I ;

ROMANO, P .

ARTHRITIS AND RHEUMATISM, 1993, 36 (11) :1566-1574

← 1 2 3 4 5 6 7 8 9 10 →